Thiophenecarboxamide derivatives activated by EthA kill mycobacterium tuberculosis by inhibiting the CTP synthetase PyrG
Nenhuma Miniatura disponível
Data
2015-07-23
Autores
Mori, Giorgia
Chiarelli, Laurent R.
Esposito, Marta
Makarov, Vadim
Bellinzoni, Marco
Hartkoorn, Ruben C.
Degiacomi, Giulia
Boldrin, Francesca
Ekins, Sean
Ribeiro, Ana Luisa de Jesus Lopes
Título da Revista
ISSN da Revista
Título de Volume
Editor
Elsevier B. V.
Resumo
To combat the emergence of drug-resistant strains of Mycobacterium tuberculosis, new antitubercular agents and novel drug targets are needed. Phenotypic screening of a library of 594 hit compounds uncovered two leads that were active against M. tuberculosis in its replicating, non-replicating, and intracellular states: compounds 7947882 (5-methyl-N-(4-nitrophenyl)thiophene-2-carboxamide) and 7904688 (3-phenyl-N-[(4-piperidin-1-ylphenyl)carbamothioyl]propanamide). Mutants resistant to both compounds harbored mutations in ethA (rv3854c), the gene encoding the monooxygenase EthA, and/or in pyrG (rv1699) coding for the CTP synthetase, PyrG. Biochemical investigations demonstrated that EthA is responsible for the activation of the compounds, and by mass spectrometry we identified the active metabolite of 7947882, which directly inhibits PyrG activity. Metabolomic studies revealed that pharmacological inhibition of PyrG strongly perturbs DNA and RNA biosynthesis, and other metabolic processes requiring nucleotides. Finally, the crystal structure of PyrG was solved, paving the way for rational drug design with this newly validated drug target.
Descrição
Palavras-chave
Como citar
Chemistry & Biology, v. 22, n. 7, p. 917-927, 2015.